Infusion and injection-related reactions, along with respiratory and urinary tract infections, emerged as the most reported adverse events in people with MS (pwMS) participating in anti-CD20 MS clinical trials (5, 12). The gene discussed is MS4A1; the disease is urinary tract infection.